Latest research on Valsartan

Valsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.

Latest findings

In addition to dabigatran, the other medications included verapamil, Budesonide, Valsartan, and hydrochlorotiazide. [source, 2016]
Losartan and Valsartan, both ARBs, have been proven to be “not inferior” to Captopril, an ACEI, in patients with AMI and heart failure and/or LV systolic dysfunction [8-10]. [source, 2016]
In AMI patients with heart failure and/or LV dysfunction, the efficacy of ARBs compared to ACEIs for secondary prevention of MACEs has been tested in two large-scale randomized clinical studies (RCTs): OPTIMAAL (Optimal Trial in Myocardial Infarction with Angiotensin II antagonist Losartan) and VALIANT (Valsartan in Acute Myocardial Infarction Trial) [8,10]. [source, 2016]
In VALIANT, Valsartan was “non-inferior” to Captopril in patients with high risk for MACE after AMI. [source, 2016]
In the present study, we excluded patients who had already received ACEIs or ARBs before hospitalization, whereas in VALIANT, 39.4% of the Valsartan group and 38.5% of the Captopril group received non-study ACEIs for an average of 5 days after the AMI, but before randomization [10]. [source, 2016]
LCZ696 is a novel molecule that combines the neprilysin inhibitor prodrug AHU377 with the angiotensin II receptor blocker (ARB) Valsartan [95]. [source, 2016]
The phase II Prospective Comparison of ARNI (angiotensin receptor neprilysin inhibitor) with ARB on Management of Heart Failure with Preserved Ejection Fraction (PARAMOUNT) trial, which compared the LCZ696 against Valsartan for 12 weeks in 301 patients, yielded some results [96]. [source, 2016]
A larger phase III trial (Efficacy and Safety of LCZ696 Compared with Valsartan, on Morbidity and Mortality in Heart Failure Patients with Preserved Ejection Fraction [PARAGON-HF], Clinical-Trials.gov Identifier: NCT01920711) is ongoing, in which LCZ696 will be compared with Valsartan on clinical end-points in HFPEF. [source, 2016]
Irbesartan, Candesartan and Valsartan displayed high concentration (Table 6). [source, 2016]
LCZ696 combines a Valsartan molecule (angiotensin II receptor antagonist) and sacubitril (inhibitor of neprilysin, which metabolizes natriuretic peptides, urodilatin, bradykinin and adrenomedullin). Experimental studies showed attenuation of ventricular cavity dilation and myocardial fibrosis after MI, for example. [source, 2016]